Reuters logo
BRIEF-RiboQuark announces enrollment of first patient in China for key trial with a Sirna drug candidate
November 13, 2017 / 12:14 PM / 10 days ago

BRIEF-RiboQuark announces enrollment of first patient in China for key trial with a Sirna drug candidate

Nov 13 (Reuters) - Kunshan RiboQuark Pharmaceutical Technology Co., Ltd. -

* RiboQuark Pharmaceutical Technology Co., Ltd., announces enrollment of the first ever patient in China for a pivotal clinical trial with a Sirna drug candidate as part of a global clinical study of the ocular neuroprotectant QPI-1007 Source text for Eikon:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below